
Cellarity is a therapeutics company that leverages AI and single-cell omics data to revolutionize drug discovery. By integrating advanced biological and computational technologies, Cellarity aims to develop transformative medicines that address cellular dysfunction across a wide range of diseases. Their unique platform allows for the design of drugs without starting from a specific target, thus unlocking insights into disease biology that traditional methods cannot achieve. Founded in 2019, Cellarity is positioned to significantly enhance the success rate and speed of drug development, making it a compelling opportunity for investors interested in innovative biotech solutions.

Cellarity is a therapeutics company that leverages AI and single-cell omics data to revolutionize drug discovery. By integrating advanced biological and computational technologies, Cellarity aims to develop transformative medicines that address cellular dysfunction across a wide range of diseases. Their unique platform allows for the design of drugs without starting from a specific target, thus unlocking insights into disease biology that traditional methods cannot achieve. Founded in 2019, Cellarity is positioned to significantly enhance the success rate and speed of drug development, making it a compelling opportunity for investors interested in innovative biotech solutions.
Company: Cellarity — therapeutics company using single-cell biology and AI for drug discovery
Headquarters: Somerville, Massachusetts, United States
Founded: Founded by Flagship Pioneering; launch circa 2017–2019
Stage / Funding: Raised Series B ($123M) and Series C ($121M); total funding reported ~$274M
Tech / Focus: Single-cell omics, genomics, machine learning, AI-driven cellular-state modeling
Drug discovery for diseases driven by cellular dysfunction; discovering medicines at the level of the cell rather than single molecular targets.
2017
Biotechnology
123000000
Series B announced February 25, 2021; included contributions from funds/accounts managed by BlackRock, The Baupost Group, Banque Pictet and Flagship Pioneering
121000000
Series C announced October 4, 2022; participating investors included Flagship Pioneering, Kyowa Kirin, and Hanwha Impact Partners
“Includes participation from Flagship Pioneering, institutional and strategic investors such as BlackRock, The Baupost Group, Banque Pictet, Kyowa Kirin, and Hanwha Impact Partners”
you could join a rapidly growing company and play a critical role in bringing new medicines to patients through looking at and treating disease in a revolutionary way. : Cellarity is seeking an experienced and highly motivated with expertise in to play a vital role in the company’s efforts to enhance and expand our perturbation data engine. The candidate will be responsible for planning and executing large-scale data generation efforts, working with CROs and managing junior scientists. The successful candidate will work cross-functionally, particularly with our Machine Learning, and Biology teams to build meaningful datasets that drive our Foundation Models. The ideal candidate must be independent, goal oriented, have excellent communication skills, be willing to learn new skills and work in a fast-paced entrepreneurial environment. - Lead from the bench data generation efforts to support our expanding platform capabilities - Plan and execute Next Generation Sequencing (NGS) experiments - Develop and execute CRISPR based perturbation screens - Manage CROs and mentor junior scientists - Collaborate with scientists from Machine Learning, Assay Development, and Exploratory Biology as part of our efforts to enhance our platform tools - Maintain detailed records of experimental protocols and data in electronic laboratory notebooks - Represent Platform Biology as a Biology Lead in Platform expansion efforts - ; MS with 15+ years of experience will be considered - Demonstrated ability leading projects and driving programs to key decisions points - Extensive experience in Next Generation Sequencing methodologies including single cell transcriptomics - Experienced managing CROs, including transfer and implementation of SOP and assays - Previous experience performing CRISPR screens (pooled or arrayed) - Excellent communication skills - Experience in hematology/immunology - Led a project team with 5-10 members - Innovative mindset focused on pushing scientific boundaries - Data-driven, willingness to abandon dogma when science leads us to new places - Strong desire to work collaboratively within and across teams - Push Boundaries: We create a legacy with breakthrough science in service of patients. - Inject Energy: We build strengths from different perspectives and tell it like it is - Own it: We transcend our job descriptions and relentlessly follow through on our commitments. - Go all out: We work quickly and with conviction. Cellarity’s mission is to fundamentally redesign the way drugs are created for the sake of bringing new hope to patients. By shifting the focus from a single target to the underlying cellular dysfunction, we unravel the complexity of disease biology and create medicines that were never before possible. The company has developed unique capabilities that link biology and chemistry with high dimensional -omic data from which we design medicines against the cellular signature of disease. The Cellarity platform allows us to uncover new biology in diseases even in the absence of known causal targets. Cellarity is a privately held, clinical-phase drug discovery startup using AI and single-cell omics to develop life-changing medicines that are unreachable by traditional methods of drug discovery. Cellarity is a product of Flagship Pioneering's venture creation engine, which has conceived and created companies such as Moderna (NASDAQ: MRNA), Generate: Biomedicines, and Lila Sciences. Cellarity is regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.